{"id":"NCT01235598","sponsor":"UCB Pharma","briefTitle":"Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)","officialTitle":"A 16-week Double-blind, Placebo-controlled (for Initial 2 Weeks) Randomized Period, Followed by a 24-week Open-label Extension to Assess Magnetic Resonance Image (MRI) - Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2012-09","completion":"2013-05","firstPosted":"2010-11-05","resultsPosted":"2014-02-05","lastUpdate":"2014-03-12"},"enrollment":41,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"OTHER","name":"Placebo","otherNames":["PBO"]},{"type":"BIOLOGICAL","name":"Certolizumab Pegol (CZP) 200 mg","otherNames":["Cimzia®","CZP","CDP870"]},{"type":"BIOLOGICAL","name":"Certolizumab Pegol (CZP) 400 mg","otherNames":["Cimzia®","CZP","CDP870"]}],"arms":[{"label":"Placebo followed by Certolizumab Pegol (CZP)","type":"OTHER"},{"label":"Certolizumab Pegol (CZP)","type":"EXPERIMENTAL"}],"summary":"Phase IIIb study to determine early response to Certolizumab Pegol (CZP) with Magnetic Resonance Imaging (MRI) score Outcome Measures in Rheumatoid Arthritis (RA) Clinical Trials (OMERACT) RA MRI Scoring System (RAMRIS) in subjects with RA.","primaryOutcome":{"measure":"Change in Synovitis Measured by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Image Scoring System (RAMRIS) Score at Week 16 Compared to Baseline for Certolizumab Pegol Arm","timeFrame":"From Baseline to Week 16","effectByArm":[{"arm":"Certolizumab Pegol (CZP)","deltaMin":-1,"sd":2.3}],"pValues":[{"comp":"OG000","p":"0.049"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":10,"countries":["Denmark","Netherlands","Poland","Sweden"]},"refs":{"pmids":["25512675"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":40},"commonTop":["Nasopharyngitis","Oropharyngeal pain","Urinary tract infection","Oral herpes","Viral infection"]}}